Immunological nanomaterials to combat cancer metastasis

Chemical Society Reviews, Journal Year: 2024, Volume and Issue: 53(12), P. 6399 - 6444

Published: Jan. 1, 2024

This review highlights recent advances in immunological nanomaterials against metastasis and summarizes various nanomaterial-mediated immunotherapy strategies.

Language: Английский

---

Cancer vaccines in the clinic

Bioengineering & Translational Medicine, Journal Year: 2023, Volume and Issue: 9(1)

Published: Oct. 27, 2023

Abstract Vaccines are an important tool in the rapidly evolving repertoire of immunotherapies oncology. Although cancer vaccines have been investigated for over 30 years, very few achieved meaningful clinical success. However, recent advances areas such antigen identification, formulation development and manufacturing, combination therapy regimens, indication patient selection hold promise to reinvigorate field. Here, we provide a timely update on status vaccines. We identify critically analyze 360 active trials according delivery vehicle, type, indication, other metrics, as well highlight eight globally approved products. Finally, discuss current limitations future applications translation

Language: Английский

---

Precisely Activating cGAS‐STING Pathway with a Novel Peptide‐Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy

Advanced Science, Journal Year: 2024, Volume and Issue: 11(15)

Published: Jan. 17, 2024

As an essential intracellular immune activation pathway, the cGAS-STING pathway has attracted broad attention in cancer treatment. However, low bioavailability, nonspecificity, and adverse effects of small molecule STING agonists severely limit their therapeutic efficacy vivo application. In this study, a peptide-based agonist is first proposed, KLA screened out to activate by promoting mitochondrial DNA (mtDNA) leakage. To precisely block PD-1/PD-L1 multi-stimuli activatable peptide nanodrug (MAPN) developed for effective delivery PD-L1 antagonist (CVR). With rational design, MAPN achieved site-specific release CVR response multiple endogenous stimuli, simultaneously activating blocking ultimately initiating robust durable T cell anti-tumor immunity with tumor growth inhibition rate 78% extending median survival time B16F10 tumor-bearing mice 40 days. Overall, antimicrobial peptides, which can promote mtDNA leakage through damaging membranes, may be potential alternatives giving new insight design novel agonists. Furthermore, presents universal platform synergy peptides.

Language: Английский

---

High Entropy 2D Layered Double Hydroxide Nanosheet Toward Cascaded Nanozyme-Initiated Chemodynamic and Immune Synergistic Therapy

Journal of the American Chemical Society, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 30, 2024

High-entropy nanomaterials (HEMs) are a hot topic in the fields of energy and catalysis. However, terms promising biomedical applications, potential therapeutic studies involving HEMs unprecedented. Herein, we demonstrated high entropy two-dimensional layered double hydroxide (

Language: Английский

---

STING in Cancer Immunoediting: Modeling Tumor-Immune Dynamics Throughout Cancer Development

Cancer Letters, Journal Year: 2025, Volume and Issue: 612, P. 217410 - 217410

Published: Jan. 16, 2025

Language: Английский

---

Boosting Antitumor Immunity via a Tumor Microenvironment‐Responsive Transformable Trifecta Nanovaccine

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: 34(26)

Published: Jan. 9, 2024

Abstract In situ tumor vaccines (ISTVs) hold great potential in immunotherapy, however, three major obstacles, including inadequate endogenous antigen uptake by dendritic cells (DCs), weak T‐cell immune responses, and stubborn immunosuppressive microenvironment (TME), still need to be fully addressed. Herein, a trifecta nanovaccine (TriNV) with TME‐responsive transformable ability is developed tri‐boost antitumor immunity. First, sufficient tumor‐associated antigens (TAAs) are liberated after immunogenic cell death induced via TriNV‐based photoimmunotherapy. the TME, soft‐transformed TriNV improves of TAAs DCs enhance acquired Second, self‐adjuvating released Mn 2+ synergistically promote DC maturation macrophage M1 polarization augmenting stimulator interferon genes activation further amplify responses. Moreover, decomposition MnO 2 within core exhausts glutathione facilitates O release alleviate hypoxia thereby overcoming chemical obstacles TME mitigate immunosuppression. Thus, remarkably eradicates primary tumors inhibits distant metastasis, thus demonstrating as feasible effective ISTV nanoplatform for combating poorly solid tumors.

Language: Английский

---

STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy

Bioactive Materials, Journal Year: 2024, Volume and Issue: 42, P. 345 - 365

Published: Sept. 6, 2024

Language: Английский

---

Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(5), P. 1346 - 1346

Published: April 27, 2023

Immunotherapy is among the most effective approaches for treating cancer. One of key aspects successful immunotherapy to achieve a strong and stable antitumor immune response. Modern checkpoint therapy demonstrates that cancer can be defeated. However, it also points out weaknesses immunotherapy, as not all tumors respond co-administration different immunomodulators may severely limited due their systemic toxicity. Nevertheless, there an established way through which increase immunogenicity immunotherapy-by use adjuvants. These enhance response without inducing such severe adverse effects. well-known studied adjuvant strategies improve efficacy metal-based compounds, in more modern implementation-metal-based nanoparticles (MNPs), are exogenous agents act danger signals. Adding innate activation main action immunomodulator makes capable eliciting robust anti-cancer The has peculiarity local administration drug, positively affects its safety. In this review, we will consider MNPs low-toxicity adjuvants could provide abscopal effect when administered locally.

Language: Английский

---

Nanoparticle targeting cGAS-STING signaling in disease therapy

Nano Research, Journal Year: 2024, Volume and Issue: 17(8), P. 7315 - 7336

Published: June 15, 2024

Language: Английский

---

A Biomimetic Autophagosomes‐Based Nanovaccine Boosts Anticancer Immunity

Advanced Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 28, 2024

Personalized cancer vaccines based on tumor cell lysates offer promise for immunotherapy yet fail to elicit a robust therapeutic effect due the weak immunogenicity of antigens. Autophagosomes, obtained from pleural effusions and ascites patients, have been identified as abundant reservoirs neoantigens that exhibit heightened immunogenicity. However, their potential personalized constrained by suboptimal lymphatic-targeting performances challenges in antigen-presenting endocytosis. Here,a reinforced biomimetic autophagosome-based (BAPs) nanovaccine generated precisely amalgamating autophagosome-derived two types adjuvants capable targeting lymph nodes is developed potently antitumor immunity. The redox-responsive BAPs facilitate cytosolic vaccine opening within cells, thereby exposing antigens stimulate strong immune response. evoke broad-spectrum T-cell responses, culminating effective eradication 71.4% established tumors. Notably, vaccination triggers enduring responses confer protection, with 100% mice shielded against rechallenge significant reduction incidence 87.5%. Furthermore, synergize checkpoint blockade therapy inhibit growth poorly immunogenic breast model. approach presents powerful formula high versatility immunotherapy.

Language: Английский

---